Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma

Phase 2

Completed

• Conditions: Multiple Myeloma
• Interventions: Drug: Thalidomide

• Registration Number: NCT00657488
• Lead Sponsor: Celgene

Brief Summary

The objective of this study is to show that thalidomide at a dose of 100 mg/d (with remedial treatment with dexamethasone if a progression occurs) is equivalent in terms of efficacy with thalidomide at 400 mg/d (with remedial treatment with dexamethasone if a progression occurs) in the treatment of refractory or relapsed multiple myeloma after at least two courses of treatment. The use of thalidomide at 100 mg/d should reduce the side effects and improve the safety of the treatment.

Detailed Description

Not available

Study Timeline

• Study Start: 2001-12-01
• Primary Completion: 2005-10-01
• Study Completion: 2006-04-01
• Study First Submitted: 2008-04-07
• Study First Submitted QC: 2008-04-11
• Study First Posted: 2008-04-14
• Status Verified: 2019-10
• Last Update Submitted: 2019-10-16
• Last Update Posted: 2019-10-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

• Patient over 18 years who has been informed about the potential risks and side effects of the treatment and having signed an informed consent to take part in the various aspects of the study.

• Having a refractory or relapsed multiple myeloma after at least two courses of treatment.

• The patients with a refractory or relapsed multiple myeloma after a single course of treatment that included an alkylating drug, can be included if there is no alternative treatment.

• Concerning the thalidomide: Agreement to use and introduction of effective contraception by all the patients:

  1. For women of childbearing potential

     • Oral estroprogestogen contraception introduced at least 1 month before the first administration of thalidomide, and continued until the first menstruation following the end of the treatment, and their partners use a condom.
     • Qualitative serum test for beta-HCG negative: to be done on Day 2 or 3 of the menstrual cycle just before the 1st prescription of thalidomide; in a context of spaniomenorrhea or amenorrhea the test should be done within 3 days after the 1st prescription of thalidomide.

  2. For post-menopausal women

     • 1st situation: Known sterility due to:

       • total hysterectomy;
       • total ovariectomy;
       • total salpingectomy

     • 2nd situation: Natural menopause

       • amenorrhea for at least 1 year and
       • negative progestagen test and
       • plasma FSH > 50 IU/l

  3. For men: Throughout the duration of the treatment and for 3 months after the end of the protocol (i.e. one spermatogenesis cycle), sexual intercourse must always be protected by using a condom.

Exclusion Criteria

• Pregnant or breast-feeding women or those of childbearing potential who are not using an effective method of contraception or the lack of protection during sexual intercourse in men.
• Patients who have already received treatment with thalidomide.
• Contraindication to thalidomide.
• Patient who has an absolute contraindication to dexamethasone.
• Patient with a history of deep vein thrombosis and who is not taking effective oral anticoagulation (the anticoagulant must be continued throughout the entire study).
• Performance index more than or equal to 3, unless the patient is bedridden as a result of the progress of the myeloma.
• Any situations that do not permit adequate follow-up of the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
B	Thalidomide	Thalidomide 400mg/day. Dexamethasone is administered at a dose of 40 mg/d, on 4 consecutive days (D1 - D4), with one course every four week in case of stable disease after 12 weeks of treatment or in case of Disease Progression
A	Thalidomide	Thalidomide 100mg/day. Dexamethasone is administered at a dose of 40 mg/d, on 4 consecutive days (D1 - D4), with one course every four week in case of stable disease after 12 weeks of treatment or in case of Disease Progression

Primary Outcome Measures

Name	Time	Method
all cause mortality	one year

Secondary Outcome Measures

Name	Time	Method
response rate	monthly

Trial Locations

Locations (49)

Hopital St Joseph; 🇧🇪 Gilly, Belgium

UCL de Mont Godine; 🇧🇪 Yvoir, Belgium

Chu D'Angers - Medecine D; 🇫🇷 Angers, France

Centre Hospitalier D'Annecy - Service d'oncohématologie; 🇫🇷 Annecy, France

Centre Hospitalier H. Duffaut - Hematologie; 🇫🇷 Avignon, France

HOPITAL JEAN MINJOZ - Médecine interne/Hématologie; 🇫🇷 Besancon, France

Centre Hospitalier de Blois - Unité d'Onco-Hématologie; 🇫🇷 Blois, France

Hopital Avicenne - Medecine Interne/Hematologie; 🇫🇷 Bobigny, France

Centre Hospitalier Du Dr Duschene - Hematologie; 🇫🇷 Boulogne Sur Mer, France

Hopital Morvan - Service Hematologie; 🇫🇷 Brest, France

Scroll for more (39 remaining)